by Vera Martinella
The results of a trial of a new treatment led to a rapid reduction of the tumor, but the study involved only three patients (and two soon had a recurrence)
It is a trial on only three patients, but the results give rise to hope for progress in the treatment of one of the most difficult tumors to treat, cerebral glioblastoma. However, great caution is needed in evaluating the results of an American study just published in the scientific journal New England Journal of Medicine, because it is the first time that a CAR-T therapy (which has already revolutionized the history of some blood tumors, to a possible recovery of patients who had only a few months to live) is tested in this neoplasm. And because the number of research participants (only three) cannot lead to any definitive conclusions.
The study and the results
«We are faced with the preliminary results of an ongoing trial obtained after having proposed the experimental treatment to three patients with glioblastoma – explains Enrico Franceschi, director of nervous system oncology at the IRCCS Institute of Neurological Sciences of Bologna -. A CAR-T therapy was performed in these patients, which specifically takes the name of CARv3-TEAM-E T. It is a therapy in which the T lymphocytes (“soldiers” of our immune system responsible for defending us from diseases) they are taken from the patient’s blood and then genetically modified to recognize specific targets on the tumor cells to be affected. In this study, T cells were targeted against a protein expressed on glioblastoma cells called EGFRvIII and reinserted into the patient’s brain ventricles. These CAR-T cells had also been trained to specifically recognize and kill cancer cells.” After treatment, researchers found a rapid reduction in tumor size in all three participants, but only one patient maintained this benefit for more than three months, while the other two developed disease regrowth within two months of the first treatment. infusion”.
Current therapies
Why is studying important? «The data suggest the possibility that CAR-T could have a role in the future in the treatment of brain tumors, and specifically against glioblastoma which today often has a severe prognosis – replies Franceschi -. Of course, the fact that the tumor recurred early in two out of three patients means that we still have to understand some mechanisms through which the cells are able to escape the T lymphocytes. Already in 2016 it had been reported, again in the New England Journal of Medicine, a good response of a glioblastoma to a CAR-T therapy directed against a different target, the interleukin 13 receptor alpha (IL13Rα2), confirming the potential efficacy of these therapeutic approaches. However, the therapeutic targets as well as the infusion routes of these cellular therapies still need to be evaluated in more depth.” What should patients now facing a glioblastoma diagnosis know? «Today the optimal treatments include surgical resection, radiotherapy and chemotherapy – concludes the expert -. However, it is extremely important to have information on the molecular picture of each patient’s glioblastoma (i.e. the genetic characteristics, ed.) both to better understand the prognosis and to evaluate the possible use of targeted drugs.”
Do you have a doubt or medical question?
Our doctors and specialists answer your questions on health topics
April 5, 2024
© ALL RIGHTS RESERVED
Do you have a doubt or medical question?
Our doctors and specialists answer your questions on health topics